Kck Ltd is an investment fund managing more than $70.4 billion ran by Raphael Metz. There are currently 3 companies in Mr. Metz’s portfolio. The largest investments include Neuropace Inc and Sight Sciences Inc, together worth $70.4 billion.
As of 25th October 2023, Kck Ltd’s top holding is 5,621,111 shares of Neuropace Inc currently worth over $54.7 billion and making up 77.7% of the portfolio value.
In addition, the fund holds 4,646,866 shares of Sight Sciences Inc worth $15.7 billion.
The third-largest holding is Aileron Therapeutics Inc worth $34 million.
Currently, Kck Ltd's portfolio is worth at least $70.4 billion. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Kck Ltd office and employees reside in Tortola, Virgin Islands, British. According to the last 13-F report filed with the SEC, Raphael Metz serves as the Secretary at Kck Ltd.
Raphael Metz disclosed a decreased stake in Sight Sciences Inc by approximately 0.1%.
This leaves the value of the investment at $15.7 billion and 4,646,866 shares.
The two most similar investment funds to Kck Ltd are Teca Partners, L.P. and Howard Hughes Medical Institute. They manage $70.4 billion and $70.4 billion respectively.
Kck Ltd’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up approximately 0.1% of
the total portfolio value.
The fund focuses on investments in the United States as
33.3% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
33% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $11.9 million.
These positions were updated on November 1st based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Neuropace Inc |
No change
5,621,111
|
$54,693,410,000 | 77.70% |
| Sight Sciences Inc |
0.09%
4,646,866
|
$15,659,938,000 | 22.25% |
| Aileron Therapeutics Inc |
No change
22,341
|
$33,958,000 | 0.05% |
| No transactions found | |||
| Showing first 500 out of 3 holdings | |||